PDS Biotechnology | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings

2025.11.13 21:22

I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.19, beating the estimate of USD -0.205.

EBIT: As of FY2025 Q3, the actual value is USD -7.271 M.

The company has not generated any revenues from commercial product sales and does not expect to generate any such revenue in the near future.

Net Loss: For the three months ended September 30, 2025, the net loss was $9.0 million, compared to $10.7 million for the same period in 2024, representing a decrease of 16%.
Research and Development Expenses: Decreased to $4.6 million for the three months ended September 30, 2025, from $6.8 million for the same period in 2024, a decrease of 33%.
General and Administrative Expenses: Increased to $3.6 million for the three months ended September 30, 2025, from $3.4 million for the same period in 2024, an increase of 6%.

Net Cash Used in Operating Activities: $24.0 million for the nine months ended September 30, 2025, compared to $26.8 million for the same period in 2024.
Net Cash Provided by Financing Activities: $8.6 million for the nine months ended September 30, 2025, compared to $20.0 million for the same period in 2024.

Stock-Based Compensation Expense: $2.9 million for the nine months ended September 30, 2025, compared to $5.2 million for the same period in 2024.

Core Business Focus: The company plans to continue funding its operations through existing cash and additional equity and/or debt financing. It anticipates needing substantial additional funding for continuing operations.
Non-Core Business: The company is exploring government funding programs and considering selectively partnering for clinical development and commercialization.
Priority: The company has identified conditions and events that raise substantial doubt regarding its ability to continue as a going concern, emphasizing the need for additional financing.